These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Pre- and intraoperative diagnostic requirements, benefits and risks of minimally invasive and robotic surgery for neuroendocrine tumors of the pancreas. Gharios J; Hain E; Dohan A; Prat F; Terris B; Bertherat J; Coriat R; Dousset B; Gaujoux S Best Pract Res Clin Endocrinol Metab; 2019 Oct; 33(5):101294. PubMed ID: 31351817 [TBL] [Abstract][Full Text] [Related]
27. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis. Cloyd JM; Kopecky KE; Norton JA; Kunz PL; Fisher GA; Visser BC; Dua MM; Park WG; Poultsides GA Surgery; 2016 Sep; 160(3):708-13. PubMed ID: 27216830 [TBL] [Abstract][Full Text] [Related]
28. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone for the PREOPANC-4 Trial. Stoop TF; Seelen LWF; van 't Land FR; van Eijck CHJ; van Santvoort HC; Besselink MG; Ann Surg Oncol; 2024 Apr; 31(4):2658-2659. PubMed ID: 38093164 [No Abstract] [Full Text] [Related]
29. ASO Author Reflections: Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors. Nigam A; Untch BR Ann Surg Oncol; 2024 Apr; 31(4):2359-2360. PubMed ID: 38252266 [No Abstract] [Full Text] [Related]
30. ASO Author Reflections: Prediction of the Chemotherapy Effect on the Prognosis of Locally Advanced Pancreatic Cancer. Tanaka M; Hackert T Ann Surg Oncol; 2023 Apr; 30(4):2409-2410. PubMed ID: 36209330 [No Abstract] [Full Text] [Related]
31. Aggressive multi-visceral pancreatic resections for locally advanced neuroendocrine tumours. Is it worth it? Abu Hilal M; McPhail MJ; Zeidan BA; Jones CE; Johnson CD; Pearce NW JOP; 2009 May; 10(3):276-9. PubMed ID: 19454819 [TBL] [Abstract][Full Text] [Related]
32. ASO Author Reflections: Endoscopic Management is Reasonable for <2 cm Duodenal Neuroendocrine Tumors. Tran CG; Sherman SK; Howe JR Ann Surg Oncol; 2022 Jan; 29(1):85-86. PubMed ID: 34608558 [TBL] [Abstract][Full Text] [Related]
33. ASO Author Reflections: A Nomogram to Predict Recurrence after Curative-Intent Resection for Neuroendocrine Liver Metastasis. Tsilimigras DI; Xiang JX; Zhang XF; Pawlik TM Ann Surg Oncol; 2020 Oct; 27(10):3727-3728. PubMed ID: 32440717 [No Abstract] [Full Text] [Related]
34. Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling. Tran CG; Scott AT; Li G; Sherman SK; Ear PH; Howe JR Surgery; 2021 Jan; 169(1):155-161. PubMed ID: 32611516 [TBL] [Abstract][Full Text] [Related]
35. ASO Author Reflections: Contact Between T and N Classifications in Pancreatic Neuroendocrine Neoplasms. Xu JZ; Wang WQ; Liu L; Yu XJ Ann Surg Oncol; 2018 Dec; 25(Suppl 3):814-815. PubMed ID: 30302639 [No Abstract] [Full Text] [Related]
36. Robotic resection of the uncinate process of the pancreas. Machado MAC; Surjan R; Basseres T; Makdissi F J Robot Surg; 2019 Oct; 13(5):699-702. PubMed ID: 30467703 [TBL] [Abstract][Full Text] [Related]
38. ASO Author Reflections: Improving Outcomes and Minimizing Variability in Pancreatic Cancer Care: A Study of Ontario and the United States. Saadat LV; Wei AC Ann Surg Oncol; 2024 Mar; 31(3):1937-1938. PubMed ID: 37865939 [No Abstract] [Full Text] [Related]
39. ASO Author Reflections: Serum Elastase 1 Level as a Risk Factor for Postoperative Recurrence in Patients with Well-Differentiated Pancreatic Neuroendocrine Neoplasms. Nanno Y; Toyama H Ann Surg Oncol; 2018 Dec; 25(Suppl 3):800-801. PubMed ID: 30136123 [No Abstract] [Full Text] [Related]